Medical Developments International
Market Cap
AU$370.7m
Last Updated
2019/11/11 10:34 UTC
Data Sources
Company Financials +
Executive Summary
Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment.
Snowflake
Fundamentals
Flawless balance sheet with high growth potential.
Share Price & News
How has Medical Developments International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MVP has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-7.2%
MVP
2.8%
AU Pharmaceuticals
0.9%
AU Market
1 Year Return
17.7%
MVP
-33.1%
AU Pharmaceuticals
11.6%
AU Market
Return vs Industry: MVP exceeded the Australian Pharmaceuticals industry which returned -33.1% over the past year.
Return vs Market: MVP exceeded the Australian Market which returned 11.6% over the past year.
Shareholder returns
| MVP | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.2% | 2.8% | 0.9% |
| 30 Day | 17.5% | -2.7% | 1.4% |
| 90 Day | 8.4% | -0.8% | 2.2% |
| 1 Year | 18.8%17.7% | -32.9%-33.1% | 18.0%11.6% |
| 3 Year | 19.9%17.0% | -43.2%-43.8% | 39.3%20.8% |
| 5 Year | 394.6%378.8% | -21.0%-28.2% | 52.3%18.3% |
Price Volatility Vs. Market
How volatile is Medical Developments International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Should You Be Concerned About Medical Developments International Limited's (ASX:MVP) ROE?1 year ago | Simply Wall St
What Investors Should Know About Medical Developments International Limited's (ASX:MVP) Financial StrengthValuation
Is Medical Developments International undervalued compared to its fair value and its price relative to the market?
351.72x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MVP (A$5.65) is trading above our estimate of fair value (A$0.71)
Significantly Below Fair Value: MVP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MVP is poor value based on its PE Ratio (351.7x) compared to the Pharmaceuticals industry average (34.6x).
PE vs Market: MVP is poor value based on its PE Ratio (351.7x) compared to the Australian market (18.6x).
Price to Earnings Growth Ratio
PEG Ratio: MVP is poor value based on its PEG Ratio (6.6x)
Price to Book Ratio
PB vs Industry: MVP is overvalued based on its PB Ratio (8.3x) compared to the AU Pharmaceuticals industry average (2.3x).
Next Steps
Future Growth
How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
53.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVP's forecast earnings growth (53.2% per year) is above the savings rate (2.3%).
Earnings vs Market: MVP's earnings (53.2% per year) are forecast to grow faster than the Australian market (9.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MVP's revenue (23.2% per year) is forecast to grow faster than the Australian market (3.6% per year).
High Growth Revenue: MVP's revenue (23.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MVP's Return on Equity is forecast to be low in 3 years time (10.4%).
Next Steps
Past Performance
How has Medical Developments International performed over the past 5 years?
-10.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MVP has high quality earnings.
Growing Profit Margin: MVP's current net profit margins (5%) are higher than last year (1.4%).
Past Earnings Growth Analysis
Earnings Trend: MVP's earnings have declined by -10.1% per year over the past 5 years.
Accelerating Growth: MVP's earnings growth over the past year (327.2%) exceeds its 5-year average (-10.1% per year).
Earnings vs Industry: MVP earnings growth over the past year (327.2%) exceeded the Pharmaceuticals industry 7.8%.
Return on Equity
High ROE: MVP's Return on Equity (2.3%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Medical Developments International's financial position?
Financial Position Analysis
Short Term Liabilities: MVP's short term assets (A$35.4M) exceeds its short term liabilities (A$8.4M)
Long Term Liabilities: MVP's short term assets (35.4M) exceeds its long term liabilities (31.8M)
Debt to Equity History and Analysis
Debt Level: MVP's debt to equity ratio (0.4%) is considered satisfactory
Reducing Debt: MVP's debt to equity ratio has reduced from 23% to 0.4% over the past 5 years.
Debt Coverage: MVP's debt is well covered by operating cash flow (11687.4%).
Interest Coverage: MVP earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: MVP has a low level of unsold assets or inventory.
Debt Coverage by Assets: MVP's debt is covered by short term assets (assets are 194.3x debt).
Next Steps
Dividend
What is Medical Developments International's current dividend yield, its reliability and sustainability?
0.71%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: MVP's dividend (0.71%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.36%).
High Dividend: MVP's dividend (0.71%) is low compared to the top 25% of dividend payers in the Australian market (5.53%).
Stability and Growth of Payments
Stable Dividend: MVP is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: MVP is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MVP is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MVP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
What is the CEO of Medical Developments International's salary, the management and board of directors tenure and is there insider trading?
0.6yrs
Average management tenure
CEO
John Sharman (53yo)
9.6yrs
Tenure
AU$643,987
Compensation
Mr. John Stewart Sharman, M.App.Fin, CA, B Ec, has been the Chief Executive Officer of Medical Developments International Limited since April 12, 2010. Mr. Sharman serves as Investment Director of CVC Vent ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD441.30K) is about average for companies of similar size in the Australian market ($USD485.71K).
Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.
Management Age and Tenure
0.6yrs
Average Tenure
Experienced Management: MVP's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Age and Tenure
6.6yrs
Average Tenure
Experienced Board: MVP's board of directors are considered experienced (6.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 4,494 |
| Max Price | AU$5.52 |
| Entity | Individual |
| Role | Member of the Board of Directors Non-Executive Director |
| Shares | 5,000 |
| Max Price | AU$3.75 |
| Entity | Company |
| Shares | 321,609 |
| Max Price | AU$3.97 |
| Entity | Individual |
| Role | Chairman of the Board Non Executive Chairman |
| Shares | 34,246 |
| Max Price | AU$3.70 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.
Management Team
John Sharman (53yo)
Chief Executive Officer
- Tenure: 9.6yrs
- Compensation: AU$643.99k
Scott Courtney
Chief Scientific Officer
- Tenure: 0.3yrs
Mark Edwards
CFO & Company Secretary
- Tenure: 2.1yrs
- Compensation: AU$249.38k
Michelle Bradney
Head of Medical Affairs
- Tenure: 1.3yrs
Wai Chi
Head of Regulatory Affairs
- Tenure: 1yrs
Neil Issa
Head of Quality
- Tenure: 0.8yrs
Matthew Cramer
Head of Project Management Office
- Tenure: 0.3yrs
Wayne Pearce
Head of Operations
- Tenure: 0.3yrs
Thomas Materia
Head of Sales & Marketing
- Tenure: 0.3yrs
Tara Collier
Head of Human Resources
- Tenure: 0.3yrs
Board Members
Philip Powell (62yo)
Non-Executive Director
- Tenure: 4.9yrs
- Compensation: AU$51.25k
David Williams (55yo)
Non Executive Chairman
- Tenure: 16.2yrs
- Compensation: AU$83.33k
R. Johnston
Non-Executive Director
- Tenure: 7yrs
- Compensation: AU$51.25k
Leon Hoare
Non-Executive Director
- Tenure: 6.2yrs
- Compensation: AU$51.25k
Company Information
Medical Developments International Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Medical Developments International Limited
- Ticker: MVP
- Exchange: ASX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$370.681m
- Shares outstanding: 65.61m
- Website: https://www.medicaldev.com
Number of Employees
Location
- Medical Developments International Limited
- 4 Caribbean Drive
- Scoresby
- Victoria
- 3179
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MVP | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Dec 2003 |
| MVP | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Dec 2003 |
Biography
Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment. The company operates in three segments: Pharmaceuticals, Medical Devices, ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/11 10:34 |
| End of Day Share Price | 2019/11/11 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.